4SC AG — Delisting Announcement 2005

Dec 15, 2005

News Details

Corporate | 15 December 2005 11:00

4SC AG: Share trading at the Frankfurt Stock Exchange

Martinsried, December 15th, 2005 . The shares of the Munich drug discovery and development company 4SC AG (ISIN DE0005753818) are being listed with effect from today, December 15th, 2005, at the Frankfurt Stock Exchange under the symbol VSC in the Regulated Market (Prime Standard).

The listing at the Stock Exchange was not linked to a share capital increase. On the occasion of a share capital increase prior to listing, the company secured 10.16 million euros. ‘These funds are to be used for further extension of our product pipeline’, as explained by Ulrich Dauer, Chief Executive Officer of 4SC AG. The company plans for the coming year the start of the clinical phase IIa for the most advanced project to treat rheumatoid arthritis. In addition, 4SC intends to take one to two further projects to the clinical development phase in 2006.

The proportion of freely tradable shares of 4SC AG is in the region of 25 percent. This corresponds mainly to 2.4 million shares out of the most recent financing round subscribed at the rate of 4.24 euros per share. Shares held by investors of earlier financing rounds, as well as by founders of the company and by the Management are subject to obligatory retention (lock ups) of up to 24 months. Since commencing to trade in 1999, the company has secured 44 million euros and employs at present 55 people.

The prelisting share capital increase as well as the listing were accompanied by Conrad Hinrich Donner Bank AG, Hamburg. Close Brothers Seydler AG and VEM Aktienbank AG act as designated sponsors.

**About 4SC:

**4SC develops novel drug candidates for inflammatory diseases and cancer using a cheminformatics based technology platform. Traditional high throughput screening of therapeutic agents has been transferred from the lab to the computer. Thus, the company offers substantial cost and time advantages as well as increased success rates in drug development. 4SC uses its patented technology platform to create a sustainable product pipeline for active agents that are developed in early clinical phases (‘proof of concept’) and subsequently result in upfront and milestone payments as well as participation in sales generated by out-licensed products to the pharmaceutical industry. The pipeline currently has five projects, the first of which, on the treatment of rheumatoid arthritis, has successfully completed clinical phase I. Preparations for the conduct of the IIa clinical phase are well under way. A further one to two other product candidates should go into clinical development in 2006. Furthermore, the company has its technology platform in co-operation projects with biotech and pharma companies and is already generating initial revenues.

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.